Table 5.

Maintenance Phase Treatment: Immunosuppressive Drugs Used at the Last Follow-Up; n of Patients Receiving Each Immunosuppressive Drug/Total n of Patients Receiving Immunosuppressive Drugs (%)

Maintenance Phase Treatment	MOG-IgG + ON	AQP4-IgG + ON	p-value
Immunosuppressive drugs used at the last follow-up, n of patients (%)	7 (43.7)	32 (74.4)	0.027*
● Azathioprine	4/7 (57.1)	13/32 (40.6)
● Rituximab	2/7 (28.6)	3/32 (9.4)
● MMF	1/7 (14.3)	14/32 (43.8)
● IVCY	0/7 (0.0)	2/32 (6.2)

Note: *Statistically significant (p < 0.05).

Abbreviations: ON, optic neuritis; MOG-IgG +, myelin oligodendrocyte glycoprotein autoantibody-positive; AQP4-IgG +, aquaporin-4 autoantibody-positive; n, number; MMF, mycophenolate mofetil; IVCY, intravenous cyclophosphamide.